Don't get left behind! The modernized ClinicalTrials.gov is coming. Check it out now.
Say goodbye to ClinicalTrials.gov!
The new site is coming soon - go to the modernized ClinicalTrials.gov
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Longitudinal Multidimensional Population Study on Brain Aging (InveCeAb)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01345110
Recruitment Status : Completed
First Posted : April 29, 2011
Last Update Posted : December 11, 2015
Sponsor:
Collaborators:
Alzheimer Federation Italy
Mario Negri Institute for Pharmacological Research
University of Pavia
Camillo Golgi Geriatric Institute
Information provided by (Responsible Party):
Antonio Guaita, MD, Fondazione Golgi Cenci

Brief Summary:

Longitudinal observational study of cognitive functions, physical health and biological parameters in the whole population living in Abbiategrasso born between 1935 and 1939,1773 subjects, followed for six years in order to know the prevalence and the incidence of dementia and risk and protective factors of normal and pathological mental aging.

The peculiarities of this study that must assure the outcome efficacy are:

  • Selected age: since 70-75 years old people represents a transition age from adulthood to old age, it is of special interest to study the evolution of psychic and physical functions of this population
  • Whole population not a sample study
  • Location: the small area involved (Abbiategrasso is a town of 30.000 inhabitants)can contribute to guarantee more homogeneity among the subjects and reduce undesired variability
  • multidimensional assessment(biological, clinical, social, psychological data collected) After initial screening, the recruited population will be followed up for two more times (every two years )

Condition or disease
Dementia Alzheimer Disease Vascular Dementia

Detailed Description:

Background:

Dementia is one of the most troubling neurodegenerative syndrome whose prevalence and incidence is strongly increasing. The etiology and physiopathology of the process that causes dementia are still controversial and largely unknown. So it is of paramount importance to isolate risk and protection factors related to dementia syndrome and Alzheimer disease. These meager known factors (biological, as well as social and neuropsychological) can be better investigated through a multidimensional longitudinal study in a homogeneous population by age and place.

Method:

People belonging to the selected population (1773 subjects living in Abbiategrasso and born between 1935 - 1939) were invited to participate at a comprehensive assessment which was divided in two appointments:

  • a first appointment (about 1 hour and half) for blood sample, social questionnaire, anthropometric and walking speed evaluation ;
  • a second one (2 hours)for clinical examination and neuropsychological assessment of mood and cognitive function.

Recruitment. People were recruited through several steps:

  • involvement of the family doctor;
  • a general call, based on age group(1935,1936, 1937, 1938, 1939), since to be born in the same year is an identity mark for these generations;
  • kick-off meetings for each age class explaining aims and methods of the research, followed by a party with music, plays and some lotteries
  • a letter with the date of the appointment followed by the phone call whenever the phone number is available
  • further letters and call until either a rejection or an appointment was taken.

Assessment. Professionals and instruments:

  • Trained interviewers, one social worker and two nurses, administer the social questionnaire that is partly derived from the CERAD and from other longitudinal studies.
  • Trained psychologists administer a neuropsychological battery exploring mood (GDS 15 items), verbal and visual memory (Rey 15-item Memory Test, and the Rey-Osterrieth Complex Figure Test (ROCF) recall; Babcock Story Recall Test ), executive function ( TMTA and TMTB; copy of ROCF), attention (Numerical Attention), abstract reasoning (Raven's Coloured Progressive Matrices), screening cognitive test (Clock test and MMSE).
  • Clinical interview and visit are executed by expert geriatricians, members of the same geriatric staff who apply diagnostic criteria for dementia (DSM IV), Alzheimer disease (NINCDS ADRDA diagnostic criteria); Vascular dementia (NINDS -AIREN criteria); Lewy Body dementia (third report, DLB consortium); frontotemporal dementia ( 2002 modified Consensus conference criteria). Other cognitive problems were classified as Mild Cognitive Impairment (MCI) following Petersen's criteria or Cognitive Impairment No Dementia (CIND) when cognitive impairments are in areas other than memory and they do not meet whole criteria for dementia. Every diagnostic conclusion is revised by another doctor; in case of discrepancies a third geriatrician, chief of the study, intervenes to arbitrate.

All the instruments were pre tested for inter rater reliability in a similar population attending a geriatric day hospital, and some general agreement sessions were performed before and during the screening.

Layout table for study information
Study Type : Observational
Actual Enrollment : 1321 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: A Longitudinal Population Study on Brain Aging and Mental Performances for the 1935-1939 Born People Living in Abbiategrasso (a Small Town Near Milan)
Study Start Date : November 2009
Actual Primary Completion Date : December 2015
Actual Study Completion Date : December 2015





Primary Outcome Measures :
  1. The proportion of the recruited persons who will develop Dementia syndrome, Alzheimer disease, Vascular dementia, Lewy Body dementia, frontotemporal dementia, Mild Cognitive Impairment, Cognitive Impairment No Dementia [ Time Frame: six years ]

    These are the criteria used for the definitions :

    • DSM IV for Dementia syndrome
    • NINCDS ADRDA diagnostic criteria for Alzheimer disease
    • NINDS -AIREN criteria for Vascular dementia
    • Third report, DLB consortium for Lewy Body dementia
    • 2002 modified Consensus Conference criteria for frontotemporal dementia
    • Report of the MCI Working Group of the European Consortium on Alzheimer's Disease for Mild Cognitive Impairment (MCI)
    • Absence of the first criteria for MCI (subjective complain) for the definition of Cognitive Impairment No Dementia (CIND)


Secondary Outcome Measures :
  1. The proportion of persons who will exhibit a performance decrease equal or more than of 1,5 standard deviation of the mean in the reference population in screening cognitive tests or in memory tests (verbal and visual memory) or in executive tests [ Time Frame: six years ]
    • Screening cognitive tests: Clock test and MMSE.
    • Memory tests: Babcock Story Recall Test , Rey 15-item Memory Test, and the Rey-Osterrieth Complex Figure Test (ROCF) recall.
    • Executive tests:Trial making A and B; copy of ROCF

  2. Neuropsychological baseline features of the persons who will develop dementia or cognitive impairment [ Time Frame: six years ]
    • Mood: GDS 15 items
    • Verbal and visual memory: Babcock Story Recall Test, Rey 15-item Memory Test, and the Rey-Osterrieth Complex Figure Test (ROCF) recall
    • Executive function: TMTA and TMTB; copy of ROCF
    • Attention: Numerical Attention
    • Abstract reasoning: Raven's Coloured Progressive Matrices
    • Screening cognitive test: Clock test and MMSE

  3. Clinical baseline features of the persons who will develop dementia or cognitive impairment [ Time Frame: six years ]
    • Index of co morbidities as defined by CIRS (Cumulative Index Rating Scale)
    • Standard neurological examination

  4. Social baseline features of the persons who will developed dementia or cognitive impairment [ Time Frame: six years ]
    • Stressful life events as defined in GALES (Geriatric Adverse Life Event Scale)
    • Physical activity
    • Social network

  5. Genetic baseline features of the persons who will developed dementia and/or cognitive impairment [ Time Frame: six years ]
    • ApoE
    • Inflammatory cytokines


Biospecimen Retention:   Samples With DNA
whole blood and serum


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   70 Years to 75 Years   (Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
All the 1773 residents of Abbiategrasso, a town of 30.000 inhabitants near Milan, Lombardy, Italy, born from 1935 to 1939 : 1724 subjects meets the inclusion criteria
Criteria

Inclusion Criteria:

  • to be resident in Abbiategrasso
  • to be born between 1935 and 1939

Exclusion Criteria:

  • to refuse to participate
  • te be not contactable in any way (mail, telephone)
  • to be legally resident, but actually living somewhere else

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01345110


Locations
Layout table for location information
Italy
Golgi Cenci Foundation
Abbiategrasso, Milan, Italy, 20081
Sponsors and Collaborators
Fondazione Golgi Cenci
Alzheimer Federation Italy
Mario Negri Institute for Pharmacological Research
University of Pavia
Camillo Golgi Geriatric Institute
Investigators
Layout table for investigator information
Study Director: ANTONIO GUAITA, MD Golgi Cenci Foundation (research and study on aging)
Additional Information:
Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Antonio Guaita, MD, director, Fondazione Golgi Cenci
ClinicalTrials.gov Identifier: NCT01345110    
Other Study ID Numbers: 01
First Posted: April 29, 2011    Key Record Dates
Last Update Posted: December 11, 2015
Last Verified: December 2015
Keywords provided by Antonio Guaita, MD, Fondazione Golgi Cenci:
dementia
mild cognitive impairment
prevalence
incidence
elderly
longitudinal study
population study
Additional relevant MeSH terms:
Layout table for MeSH terms
Alzheimer Disease
Dementia
Dementia, Vascular
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Tauopathies
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders
Cerebrovascular Disorders
Intracranial Arteriosclerosis
Intracranial Arterial Diseases
Leukoencephalopathies
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases
Cardiovascular Diseases